Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the efficacy of two different treatment regimens of etanercept in psoriasis subjects with psoriatic arthritis with respect to both the skin and joint manifestations.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• 18 years of age or older at time of consent

• Active Psoriatic Arthritis

• Clinically stable, plaque psoriasis involving more than 10% of the body surface area

Exclusion Criteria:

• Evidence of skin conditions other than psoriasis that would interfere with skin examinations.

• Systemic anti-psoriasis therapy or DMARD within 28 days of study drug initiation

• Prior exposure to any TNF-inhibitor, including etanercept